GlassScriptPhysician profile
Earl J Craig
NPI 1912989716
$1,071.78
in general payments reported to CMS, 2019-2025
24 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $99.55 · 2021: $136 · 2022: $60.46 · 2023: $43.67 · 2024: $69.47 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350 · Consulting Fee: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $350.29 |
| Consulting Fee | $120.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mml US, INC. | $146.77 | 2025 | Reactiv8 |
| Pfizer INC. | $107.44 | 2019-2021 | |
| Si-Bone, INC. | $98.64 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $81.67 | 2019-2025 | |
| Saluda Medical Americas, INC. | $80.41 | 2025 | Evoke |
| Tersera Therapeutics LLC | $64.20 | 2019 | |
| Almatica Pharma LLC | $57.65 | 2021 | |
| Abbvie INC. | $53.56 | 2022-2025 | |
| Horizon Therapeutics Plc | $46.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.52 | 2020-2021 | |
| Radius Health, INC. | $31.11 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.68 | 2022-2023 | Seglentis |
| Averitas Pharma INC. | $26.34 | 2024 | Qutenza |
| Depuy Synthes Sales INC. | $25.77 | 2021 | |
| Boston Scientific Corporation | $24.24 | 2024 | Wavewriter Alpha Prime 16 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $23.25 | 2025 | |
| Globus Medical, INC. | $21.70 | 2025 | Senza |
| Abbott Laboratories | $20.11 | 2022 | |
| Valinor Pharma, LLC | $17.70 | 2025 | Movantik |
| Arbor Pharmaceuticals, INC. | $16.85 | 2020 | |
| Biodelivery Sciences International, INC. | $16.75 | 2021 | |
| Nevro Corp. | $15.36 | 2023 | Senza |
| Pacira Pharmaceuticals Incorporated | $14.79 | 2023 | Zilretta |
| Iroko Pharmaceuticals, LLC | $14.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Craig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.